| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 79, 1752-1758, Copyright © 1994 by Endocrine Society
ARTICLES |
SK Durham, BL Riggs and CA Conover
Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905.
Insulin-like growth factor-binding protein-4 (IGFBP-4) is secreted by normal human osteoblast-like (hOB) cells and acts as a potent inhibitor of IGF action. hOB cells also secrete a protease, which requires IGFs for activation and specifically cleaves IGFBP-4. To study the regulation of this IGFBP-4 protease, hOB cells from 26 different adult donors were cultured in serum-free medium for 24 h in the absence or presence of hormones and other factors known to regulate bone growth. hOB cell-conditioned medium (hOB-CM) was collected for measurement of IGFBP-4 protease activity in a cell-free assay. This assay involved incubation of hOB-CM (50 microL) without or with IGF-II at 37 C for 6 h. IGF-II-activated IGFBP-4 hydrolysis was assessed by Western ligand blotting and quantitated using laser densitometry. Conditioned medium from all hOB cells examined exhibited IGFBP-4 protease activity. PTH, GH, insulin, calcitonin, glucocorticoids, sex steroids, 1,25- dihydroxyvitamin D3, and epidermal growth factor had no significant effect on IGF-dependent IGFBP-4 protease activity. In comparison, hOB- CM from cells treated with transforming growth factor-beta (TGF beta) exhibited significantly augmented IGF-II-dependent proteolysis of endogenous IGFBP-4. Enhanced proteolysis of exogenous IGFBP-4 was also demonstrated: 1) 92% of recombinant human IGFBP-4 added to conditioned medium from TGF beta-treated hOB cells was hydrolyzed during the assay in the presence of IGF-II compared to 45% of recombinant human IGFBP-4 added to control hOB-CM; and 2) increased radiolabeled IGFBP-4 fragments were generated in conditioned medium from TGF beta-treated hOB cells compared with control hOB-CM in the presence of IGF-II. In addition to its effect on IGFBP-4 proteolysis, TGF beta treatment decreased IGFBP-4 messenger ribonucleic acid expression, as measured by Northern analysis. Our results indicate that the IGFBP-4-IGFBP-4 protease system in hOB cells can be controlled by two of the most abundant local growth factors for bone (IGF-II and TGF beta), with each acting via different mechanisms. Regulation of IGFBP-4 availability may play an important role in the modulation of bone cell responsiveness to IGFs.
This article has been cited by other articles:
![]() |
S. M. Firth and R. C. Baxter Cellular Actions of the Insulin-Like Growth Factor Binding Proteins Endocr. Rev., December 1, 2002; 23(6): 824 - 854. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-K. Chen, M. T. Overgaard, L. K. Bale, Z. T. Resch, M. Christiansen, C. Oxvig, and C. A. Conover Molecular Regulation of the IGF-Binding Protein-4 Protease System in Human Fibroblasts: Identification of a Novel Inducible Inhibitor Endocrinology, April 1, 2002; 143(4): 1199 - 1205. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fernandez-Celemin and J.-P. Thissen Interleukin-6 Stimulates Hepatic Insulin-Like Growth Factor Binding Protein-4 Messenger Ribonucleic Acid and Protein Endocrinology, January 1, 2001; 142(1): 241 - 248. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Miyakoshi, C. Richman, X. Qin, D. J. Baylink, and S. Mohan Effects of Recombinant Insulin-Like Growth Factor-Binding Protein-4 on Bone Formation Parameters in Mice Endocrinology, December 1, 1999; 140(12): 5719 - 5728. [Abstract] [Full Text] |
||||
![]() |
R. Rajah, R. V. Nachajon, M. H. Collins, H. Hakonarson, M. M. Grunstein, and P. Cohen Elevated Levels of the IGF-Binding Protein Protease MMP-1 in Asthmatic Airway Smooth Muscle Am. J. Respir. Cell Mol. Biol., February 1, 1999; 20(2): 199 - 208. [Abstract] [Full Text] |
||||
![]() |
W. A. Price Peptide Growth Factors Regulate Insulin-Like Growth Factor Binding Protein Production by Fetal Rat Lung Fibroblasts Am. J. Respir. Cell Mol. Biol., February 1, 1999; 20(2): 332 - 341. [Abstract] [Full Text] |
||||
![]() |
X. Qin, D. D. Strong, D. J. Baylink, and S. Mohan Structure-Function Analysis of the Human Insulin-like Growth Factor Binding Protein-4 J. Biol. Chem., September 4, 1998; 273(36): 23509 - 23516. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Horney, D. W. Shirley, D. T. Kurtz, and S. A. Rosenzweig Elevated glucose increases mesangial cell sensitivity to insulin-like growth factor I Am J Physiol Renal Physiol, June 1, 1998; 274(6): F1045 - F1053. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ohlsson, B.-A. Bengtsson, O. G. P. Isaksson, T. T. Andreassen, and M. C. Slootweg Growth Hormone and Bone Endocr. Rev., February 1, 1998; 19(1): 55 - 79. [Abstract] [Full Text] |
||||
![]() |
S. Rajaram, D. J. Baylink, and S. Mohan Insulin-Like Growth Factor-Binding Proteins in Serum and Other Biological Fluids: Regulation and Functions Endocr. Rev., December 1, 1997; 18(6): 801 - 831. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |